NIH Foreign Co-Author Rules and Publications: What Researchers Need to Know in 2026

On May 22, 2026, the NIH Office of Extramural Research published NOT-OD-26-084, a notice titled "Reminder: Definition of Foreign Components." The notice was positioned as a clarification, not a new rule. But the coverage that followed in Science and Inside Higher Ed painted a more complicated picture: several NIH Institutes and Centers had been directing grantees, individually and informally, to obtain prior approval before publishing papers that included co-authors affiliated with foreign institutions. Some grantees had been asked to remove already-published papers from annual progress reports if those papers listed foreign co-authors whose involvement had not been previously approved as a foreign component.

The result has been genuine confusion for working researchers. NIH's official position, restated in the notice, is that it has not expanded or changed the definition of a foreign component. But universities from Washington to North Carolina have since issued internal compliance guidance urging faculty to check with their grants administrators before finalizing any manuscript that names a foreign-affiliated collaborator. If you are an NIH-funded medical researcher with international colleagues, you need to understand what the policy actually says, where the ambiguity lives, and what steps reduce your risk before the next submission.

What "Foreign Component" Has Always Meant

The NIH Grants Policy Statement defines a foreign component as "the performance of any significant scientific element or segment of a project outside of the United States, either by the recipient or by a researcher employed by a foreign organization, whether or not grant funds are expended." NOT-OD-26-084 did not change this definition. What it did was clarify how NIH expects grantees to apply it, particularly in the context of publications.

Two phrases in that definition carry significant weight. "Significant scientific element" is a judgment call rather than a bright line. NIH has long acknowledged that minor contributions, such as providing a single reagent that results in co-authorship, may not constitute an actual foreign component even if the contributor is a researcher at a foreign institution. What counts as "significant" has never been formally codified in a way that applies uniformly across all study types and all Institutes, which is precisely where interpretive disputes arise.

"Whether or not grant funds are expended" is the phrase that surprises many researchers. A researcher at a US university who collaborates with a colleague at a European institution, where the European colleague contributes no-cost scientific work to the project, can still trigger a foreign component classification if the contribution is judged significant enough. The money does not have to cross a border. The science does.

How Publications Became the New Scrutiny Point

For most of NIH's history, foreign component oversight focused primarily on subawards, subcontracts, and research activities physically occurring at foreign sites. Publications rarely drew separate scrutiny. That has shifted, and the shift appears to have several overlapping drivers.

Research security concerns, including the risk of undisclosed foreign affiliations and technology transfer through scientific collaboration, have elevated the stakes for cross-border work across the federal government. The expanded foreign influence disclosure requirements introduced by NIH and other agencies since 2018 made institutions more attentive to how publication authorship can surface international connections that were not declared in the original grant application. A paper with a foreign co-author can reveal a collaboration that, if it involved significant scientific contribution, should have been reported to the funding Institute.

NIH also specifically noted in a June 2026 Extramural Nexus item that "affiliations in publications can reveal undisclosed foreign collaborations/components" and that publications should accurately reflect where work was performed. That framing effectively treats the journal submission as a compliance document as well as a scientific one.

Which Grants Are Most Affected

Not every NIH award is equally exposed. The critical question is whether the Notice of Funding Opportunity that created your award explicitly excludes foreign components. Some NOFOs, particularly those in areas with national security dimensions such as biosecurity, dual-use research of concern, or research touching on sensitive technologies, have long-standing restrictions on foreign components. For researchers holding those awards, the current enforcement environment is not new in principle. It is simply being applied more carefully to publications that previously escaped scrutiny.

Awards that do not formally exclude foreign components can still include international collaborators, provided those collaborators and their contributions are disclosed appropriately in the application and in progress reports. The risk comes from failing to report a collaboration that was added after the initial award, or from assuming that a published collaboration with a foreign co-author does not need to be tracked because no grant money left the country.

The Prior Approval Question

The most operationally significant aspect of the current environment is that some NIH Institutes are directing grantees to request prior approval before publishing papers with foreign co-authors. Science magazine's May 2026 reporting, subsequently confirmed by compliance communications from multiple universities, documented this practice. It is not reflected in any publicly issued guidance document from NIH. It is being communicated by program officers to investigators individually.

NIH is a decentralized organization. Each Institute sets many of its own practices within the framework of NIH-wide policy. What a program officer at one Institute has communicated to its grantees may not be the same as what a program officer at another Institute has communicated. Researchers who are not in regular contact with their program officers, or whose institutions have not yet circulated internal guidance, may be operating without knowing that an approval step applies to their grant.

This informality is itself a compliance risk. When requirements are communicated informally rather than through published policy, the burden falls on the researcher to ask the right questions. NIH's own June 2026 guidance explicitly tells recipients to "report foreign co-authorship to the funding Institute or Center as soon as they are aware of it to determine what steps, if any, need to be taken." That is a prompt to reach out proactively, not a reassurance that no steps are required.

What to Do Before Your Next Submission

Given the current state of play, practical advice is possible even where the policy boundary is not perfectly clear.

Start by reading your award's NOFO closely. Search the text for "foreign component" and "foreign institution" and record what the document says. If the NOFO restricts or excludes foreign components, any co-author affiliated with a foreign institution is a matter to handle before submission, not after revision.

Contact your institution's sponsored programs office or research compliance team. Universities including Northwestern, University of Washington, Penn State, and Brown University have issued internal guidance on this topic and their compliance teams are best positioned to interpret what your specific award requires. They also have existing relationships with NIH program officers that allow them to ask targeted questions on your behalf.

If you have a foreign-affiliated collaborator who contributed substantively to the work, contact your NIH program officer in writing before finalizing the manuscript. Ask whether the collaboration constitutes a foreign component under your award and whether any prior approval is needed. Keep a record of the response. A documented exchange with your program officer is far better protection than an informal assumption that everything is fine.

Before finalizing the manuscript, check the affiliations listed for every co-author and confirm that they reflect where the work was actually performed. An affiliation that does not match the location of the scientific contribution can itself create a discrepancy between the paper and what has been reported to NIH. If a co-author moved institutions between performing the work and submitting the manuscript, clarify which affiliation is scientifically accurate.

Annual Progress Reports and the Retroactive Problem

One of the more disruptive aspects of the current situation involves progress reports rather than manuscript submission itself. Science magazine reported in May 2026 that some NIH ICs had directed grantees to remove published papers listing foreign co-authors from annual progress reports if a foreign component approval had not previously been obtained for those collaborations.

This creates a retroactive complication that many researchers have not yet confronted. A paper that passed external peer review and was published without incident can now create a compliance gap if it appears in a progress report and the funding IC has not approved the underlying international collaboration. The problem is not with the journal. It is with the relationship between the paper and the grant record.

If you have papers published in previous grant years that included foreign co-authors and those collaborations were not reported as foreign components at the time, raising this history with your grants administrator now, before the next progress report, is worth the awkward conversation. Voluntary disclosure is routinely treated more favorably than a discrepancy discovered during a compliance review.

The NASA Dimension

NIH is not the only federal funder applying heightened scrutiny to international publication co-authorship. NASA has been communicating to some of its grantees that papers co-authored with researchers affiliated with Chinese institutions may have violated restrictions under the Wolf Amendment. That amendment, which Congress has renewed annually since 2011, limits NASA's use of its appropriations for bilateral activities with Chinese entities, including the Chinese government and Chinese state enterprises.

For biomedical and public health researchers, NASA funding is less common than NIH funding, but not rare. Environmental health, climate-driven disease burden, air quality, and certain computational biology applications all draw NASA support. If your grant involves NASA funding in any form and you have collaborators at Chinese institutions, consult your institution's research security office about the Wolf Amendment before submission rather than after publication.

What Your Institution Is (and Should Be) Doing

Institutional research offices are the primary intermediary between individual researchers and the patchwork of NIH Institute practices. Those at the most research-intensive institutions have already begun issuing guidance. The University of Washington, Northwestern University Feinberg School of Medicine, Penn State, Brown University, University of North Carolina, and Washington University in St. Louis are among the institutions that have circulated compliance updates since the Science reporting in May 2026.

If your institution has not yet issued guidance, that does not mean the issue does not apply to you. It may mean your compliance office has not yet prioritized the communication or that the issue has not surfaced through a program officer conversation. Either way, reaching out proactively puts you in a better position than waiting.

What institutional offices cannot do is substitute for a direct conversation with your NIH program officer about your specific award. The institutional guidance is general. What applies to your grant depends on what your NOFO says and what your Institute is currently requiring.

The Broader Consequence for International Medical Research

Medical research is unusually dependent on international collaboration. Multi-site clinical trials by design involve institutions in several countries. Infectious disease epidemiology requires data from the countries where diseases emerge. Drug development regularly crosses institutional and national borders. Global health work is international by definition. The prospect of having those collaborations subjected to prior approval requirements, enforced inconsistently and without clear public standards, creates friction for science that ultimately serves patients beyond US borders.

NIH has not prohibited international co-authorship. The agency's official position remains that foreign components are permissible when properly disclosed and approved. But the gap between the official position and how some Institutes are operating creates a compliance environment that rewards researchers who communicate with their grants administrators and program officers before problems arise, not after papers are published.

The situation is still evolving. NOT-OD-26-084 was explicitly a "reminder," not a policy change. Whether NIH will issue more formal and uniform guidance, or whether the current Institute-by-Institute variation will continue, is not clear as of June 2026. What is clear is that treating foreign co-authorship on NIH-funded work as a purely scientific decision, without a parallel compliance conversation, is no longer a safe default.

Further Reading